OUR SCIENCE
An investment
in the future
RESEARCH AND DEVELOPMENT
Developing novel treatments for CNS conditions
Throughout our history, Supernus Pharmaceuticals, Inc. has built a robust research and development program. We apply proprietary technologies to develop novel treatments that are designed to improve the lives of patients with CNS conditions.
This dedication to research has resulted in a successful track record of developing and launching novel products.
Products utilizing our technologies
These technologies have been utilized to create ten marketed products, including Qelbree® (Supernus), Trokendi XR® and Oxtellar XR® (Supernus), Adderall XR®, Intuniv®, and Mydayis® (developed for Shire, now Takeda), and Orenitram® (developed for United Therapeutics Corporation).
CLINICAL TRIALS
Laying the foundation for new
therapies and innovations
Supernus Pharmaceuticals, Inc. is focused on developing products to meet the medical needs in the areas of neurology and psychiatry. To learn more about our current clinical trials for our product candidates, please visit www.ClinicalTrials.gov.
PIPELINE
Innovative product candidates
Supernus is committed to the development of innovative product candidates in neurology and psychiatry. Below are our product candidates and their status in our pipeline.
Hypomobility in Parkinson's disease
SPN-830
For the treatment of hypomobility in Parkinson’s disease
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
NDA FILING
NDA FILING
Treatment-resistant depression
SPN-820/821
For the treatment of treatment-resistant depression
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
NDA FILING
PHASE 2
Severe epilepsy
SPN-817
For the treatment of severe epilepsy
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
NDA FILING
PHASE 2
